|
|
|
Volumn 52, Issue 1341, 2010, Pages 51-52
|
|
Ofatumumab (Arzerra) for CLL
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALEMTUZUMAB;
ARZERRA;
BENDAMUSTINE;
CETIRIZINE;
CYCLOPHOSPHAMIDE;
FLUDARABINE;
FLUDARABINE PHOSPHATE;
OFATUMUMAB;
PARACETAMOL;
PREDNISOLONE;
RITUXIMAB;
UNCLASSIFIED DRUG;
ADVERSE DRUG REACTION;
ALLOTRANSPLANTATION;
CANCER SURVIVAL;
CHRONIC LYMPHATIC LEUKEMIA;
CLINICAL TRIAL;
CYTOPENIA;
DRUG COST;
DRUG HYPERSENSITIVITY;
DRUG MECHANISM;
HUMAN;
OPPORTUNISTIC INFECTION;
PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY;
SHORT SURVEY;
TREATMENT RESPONSE;
ANIMALS;
ANTIBODIES, MONOCLONAL;
ANTIGENS, CD20;
ANTINEOPLASTIC AGENTS;
HUMANS;
LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;
OPPORTUNISTIC INFECTIONS;
|
|
EID: 77954638811
PISSN: 0025732X
EISSN: None
Source Type: Journal
DOI: None Document Type: Short Survey |
|
Times cited : (4)
|
|
References (5)
|
